FAT1 Loss

CI-VAR-00002509Explore in graph →CIViC 5080

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
FAT1 Loss	CDK4/6 Inhibition	Predictive	B	Supports Resistance	3	submitted	EID12263 Drug resistance to CDK4/6 inhibitors was analyzed in a genomic study of 348 estrogen receptor-positive (ER+) breast cancer cases. Among patients treated with CDK4/6 inhibitors, those with FAT1 mutatio… (full text at CIViC) PMID 30537512 · Li et al., 2018 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.